Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab in advanced solid tumors
NCT03101488Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of envafolimab in solid tumor and hepatocellular carcinoma (HCC), sponsored by 3D Medicines Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Adverse Events at 2 years and 1 more. Started Mar 2017; status: completed.
02
Drugs
envafolimab
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03101488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101488.